Jubira 20 Tablet contains Rosuvastatin 20 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL particles from the bloodstream. This mechanism effectively reduces the risk of atherosclerotic cardiovascular disease, including myocardial infarction, stroke, and the need for coronary revascularization in patients with or at risk for cardiovascular events. Jubira 20 is indicated as an adjunct to diet and lifestyle modifications such as exercise, weight reduction, and smoking cessation. It is contraindicated in patients with active liver disease, unexplained persistent elevations of serum transaminases, and during pregnancy or lactation. Common adverse effects include headache, myalgia, abdominal pain, and nausea. Liver function tests and creatine kinase levels should be monitored periodically during therapy to detect potential hepatotoxicity or myopathy. Jubira 20 Tablet should be prescribed and used under medical supervision with appropriate patient evaluation.